Advertisement

Journal of Neurology

, Volume 265, Issue 11, pp 2548–2561 | Cite as

Risk factors of suicidal ideation in Huntington’s disease: literature review and data from Enroll-HD

  • Philipp Honrath
  • Imis Dogan
  • Olga Wudarczyk
  • Katharina S. Görlich
  • Mikhail Votinov
  • Cornelius J. Werner
  • Beate Schumann
  • Rena T. Overbeck
  • Jörg B. Schulz
  • Bernhard G. Landwehrmeyer
  • Raquel E. Gur
  • Ute Habel
  • Kathrin Reetz
  • the Enroll-HD investigators
Original Communication
  • 185 Downloads

Abstract

Suicide is a leading cause of death in Huntington’s disease (HD), following pneumonia. Up to one-fifth of individuals with HD report suicidal ideation. Identifying the risk factors of suicidal ideation in this clinical population is thus pivotal. Here, we review the literature on prevalence rates and risk factors of suicidal ideation in premanifest and manifest patients and re-evaluate them using the largest currently existing clinical dataset from the ongoing observational study “Enroll-HD” (N = 5709). Large scale studies yielded important insights regarding suicidal ideation in HD. However, estimated prevalence rates vary among studies and risk factors are still poorly understood. According to the Enroll-HD data, pre- and manifest disease stages are associated with current (5.8–10%) and a history of suicidal ideation (18.6–30.9%). Throughout the course of HD, a history of suicidal ideation and the presence of depressive symptoms were strongly associated with current suicidal ideation. However, while for premanifest individuals, socio-demographics and activities of daily living appear to be important, in manifest patients, suicidal ideation is more closely linked to anxiety, irritability, psychosis, and apathy. These results highlight the importance of treating depressive symptoms in patients with HD and addressing potential suicidal ideation during clinical monitoring. The relevance of risk factors may differ among premanifest and manifest patients.

Keywords

Huntington’s disease Depression Suicidal ideation Risk factors Enroll-HD 

Notes

Acknowledgements

This work was funded by the International Research Training Group, The Neuroscience of Modulating Aggression and Impulsivity in Psychopathology (IRTG-2150) of the German Research Foundation (DFG). KR was funded by the German Federal Ministry of Education and Research (BMBF 01GQ1402). ID was supported by the START-Program (08/16) of the Faculty of Medicine, RWTH Aachen. All authors contributed and approved the final manuscript. We thank Philippa Hüpen, Simon Koppers, and Andrei Puiu for comments on the manuscript. Enroll-HD is a longitudinal observational study for Huntington’s disease families intended to accelerate progress towards therapeutics; it is sponsored by CHDI Foundation, a non-profit biomedical research organization exclusively dedicated to developing therapeutics for HD. Enroll-HD would not be possible without the vital contribution of the research participants and their families.

Author contributions

Concept and design: PH, ID, KR, UH; acquisition of data: the Enroll-HD investigators; drafting of the manuscript: PH; critical revision of the manuscript: ID, KR, CJW, BS, RTO, OW, KSG, MV, REG, JBS, UH, BGL; statistical analyses: PH, ID.

Compliance with ethical standards

Conflicts of interest

We have read and understood the policy on declaration of conflict of interest and declare that we have no competing interests.

Patient consent

Obtained.

Ethics approval

The study design and protocol were approved by the local scientific committee (University Hospital RWTH Aachen) and were in accordance with the code of ethics of the World Medical association (Declaration of Helsinki, 1967).

Provenance and peer review

Not commissioned, externally reviewed.

References

  1. 1.
    WHO (2016) Suicide rates (per 100000 population). http://www.who.int/gho/mental_health/suicide_rates/en/. Accessed 27 Sept 2017
  2. 2.
    Nock MK, Borges G, Bromet EJ et al (2008) Cross-national prevalence and risk factors for suicidal ideation, plans and attempts. Br J Psychiatry 192(2):98–105CrossRefGoogle Scholar
  3. 3.
    Bolton JM, Gunnell D, Turecki G (2015) Suicide risk assessment and intervention in people with mental illness. BMJ 351:h4978-hCrossRefGoogle Scholar
  4. 4.
    Qin P, Nordentoft M, Hoyer EH, Agerbo E, Laursen TM, Mortensen PB (2006) Trends in suicide risk associated with hospitalized psychiatric illness: a case-control study based on Danish longitudinal registers. J Clin Psychiatry 67(12):1936–1941CrossRefGoogle Scholar
  5. 5.
    Hesdorffer DC (2016) Comorbidity between neurological illness and psychiatric disorders. CNS spectrums 21(3):230–238CrossRefGoogle Scholar
  6. 6.
    Arciniegas DB, Anderson CA (2002) Suicide in neurologic illness. Curr Treatment Options Neurol 4(6):457–468CrossRefGoogle Scholar
  7. 7.
    Huntington G (1872) On chorea. Med Surg Rep Weekly J 26(15):317–21Google Scholar
  8. 8.
    Rodrigues FB, Abreu D, Damásio J et al (2017) Survival, mortality, causes and places of death in a European Huntington’s disease prospective cohort. Movement Disorders Clinical Practice.Google Scholar
  9. 9.
    Paulsen JS, Nehl C, Hoth KF et al (2005) Depression and stages of Huntington’s disease. J Neuropsychiatry Clin Neurosci 17(4):496–502CrossRefGoogle Scholar
  10. 10.
    Baliko L, Csala B, Czopf J (2004) Suicide in Hungarian Huntington’s disease patients. Neuroepidemiology 23(5):258–260.  https://doi.org/10.1159/000079953 CrossRefPubMedGoogle Scholar
  11. 11.
    Di Maio L, Squitieri F, Napolitano G, Campanella G, Trofatter JA, Conneally PM (1993) Suicide risk in Huntington’s disease. J Med Genet 30(4):293–295CrossRefGoogle Scholar
  12. 12.
    Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N (2012) The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord 27(9):1083–1091.  https://doi.org/10.1002/mds.25075 CrossRefPubMedGoogle Scholar
  13. 13.
    Nance M, Paulsen JS, Rosenblatt A, Wheelock V (2011) A physician’s guide to the management of Huntington’s disease. Huntington’s Disease Society of America, New YorkGoogle Scholar
  14. 14.
    van Duijn E, Kingma E, van der Mast R (2007) Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 19(4):441–448CrossRefGoogle Scholar
  15. 15.
    Epping EA, Paulsen JS (2011) Depression in the early stages of Huntington disease. Neurodegener Dis Manag 5(1):407–414CrossRefGoogle Scholar
  16. 16.
    Orth M (2011) Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY. J Neurol Neurosurg Psychiatry 82(12):1409–1412CrossRefGoogle Scholar
  17. 17.
    Dorsey ER, Investigators HSGC (2012) Characterization of a large group of individuals with Huntington disease and their relatives enrolled in the COHORT study. PloS one 7(2):e29522CrossRefGoogle Scholar
  18. 18.
    Kieburtz K, Penney JB, Corno P et al (2001) Unified Huntington’s disease rating scale: reliability and consistency. Neurology 11(2):136–142Google Scholar
  19. 19.
    Langbehn DR, Hayden MR, Paulsen JS (2010) CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet Part B Neuropsychiatr Genet 153(2):397–408CrossRefGoogle Scholar
  20. 20.
    Craufurd D, Thompson JC, Snowden JS (2001) Behavioral changes in Huntington disease. Cogn Behav Neurol 14(4):219–226Google Scholar
  21. 21.
    Penney JB, Vonsattel JP, Macdonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41(5):689–692CrossRefGoogle Scholar
  22. 22.
    Beck AT, Steer RA, Brown GK (1996) Beck depression inventory-II. San Antonio 78(2):490–498Google Scholar
  23. 23.
    Posner K, Brent D, Lucas C et al (2008) Columbia-suicide severity rating scale (C-SSRS). Columbia University Medical Center, New YorkGoogle Scholar
  24. 24.
    van Duijn E, Vrijmoeth EM, Giltay EJ, Landwehrmeyer GB, Network RiotEHsD (2017) Suicidal ideation and suicidal behavior according to the C-SSRS in a European cohort of Huntington’s disease gene expansion carriers. J Affect Disord 228:194–204CrossRefGoogle Scholar
  25. 25.
    Paulsen JS, Hoth KF, Nehl C, Stierman L (2005) Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry 162(4):725–731CrossRefGoogle Scholar
  26. 26.
    Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC (2012) Suicidality in Huntington’s disease. J Affect Disord 136(3):550–557.  https://doi.org/10.1016/j.jad.2011.10.031 CrossRefPubMedGoogle Scholar
  27. 27.
    Anderson KE, Eberly S, Groves M et al (2016) Risk factors for suicidal ideation in people at risk for Huntington’s disease. J Huntingt Dis 5(4):389–394CrossRefGoogle Scholar
  28. 28.
    Wetzel HH, Gehl CR, Dellefave-Castillo L, Schiffman JF, Shannon KM, Paulsen JS (2011) Suicidal ideation in Huntington disease: the role of comorbidity. Psychiatry Res 188(3):372–376.  https://doi.org/10.1016/j.psychres.2011.05.006 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Hubers AA, van Duijn E, Roos RA et al (2013) Suicidal ideation in a European Huntington’s disease population. J Affect Disord 151(1):248–258.  https://doi.org/10.1016/j.jad.2013.06.001 CrossRefPubMedGoogle Scholar
  30. 30.
    Coustasse A, Pekar A, Sikula A, Lurie S (2009) Ethical considerations of genetic presymptomatic testing for Huntington’s disease. J Hosp Market Pub Relat 19(2):129–141CrossRefGoogle Scholar
  31. 31.
    Oquendo MA, Bernanke JA (2017) Suicide risk assessment: tools and challenges. World Psychiatry 16(1):28–29CrossRefGoogle Scholar
  32. 32.
    Silverman MM, Berman AL (2014) Suicide risk assessment and risk formulation part I: a focus on suicide ideation in assessing suicide risk. Suicide Life-Threat Behav 44(4):420–431CrossRefGoogle Scholar
  33. 33.
    Schmitz WM, Allen MH, Feldman BN et al (2012) Preventing suicide through improved training in suicide risk assessment and care: an American Association of Suicidology Task Force report addressing serious gaps in US mental health training. Suicide Life-Threat Behav 42(3):292–304CrossRefGoogle Scholar
  34. 34.
    van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, Landwehrmeyer GB (2014) Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry.  https://doi.org/10.1136/jnnp-2013-3073 CrossRefPubMedGoogle Scholar
  35. 35.
    van Heeringen K, Mann JJ (2014) The neurobiology of suicide. The Lancet Psychiatry 1(1):63–72CrossRefGoogle Scholar
  36. 36.
    Dogan I, Eickhoff SB, Schulz JB et al (2013) Consistent neurodegeneration and its association with clinical progression in Huntington’s disease: a coordinate-based meta-analysis. Neuro-Degener Dis 12(1):23–35.  https://doi.org/10.1159/000339528 CrossRefGoogle Scholar
  37. 37.
    Madsen T, Erlangsen A, Nordentoft M (2017) Risk estimates and risk factors related to psychiatric inpatient suicide—an overview. Int J Environ Res Pub Health 14(3):253CrossRefGoogle Scholar
  38. 38.
    Rossetti MC, Tosone A, Stratta P et al (2017) Different roles of resilience in depressive patients with history of suicide attempt and no history of suicide attempt. Revista Brasileira de Psiquiatria 39(3):216–219CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of NeurologyRWTH Aachen University HospitalAachenGermany
  2. 2.Department of Neurology, Section Interdisciplinary GeriatricsRWTH Aachen UniversityAachenGermany
  3. 3.Department of Psychiatry, Psychotherapy and PsychosomaticsRWTH Aachen UniversityAachenGermany
  4. 4.JARA-BRAIN, Jülich-Aachen Research AllianceInstitute of Molecular Neuroscience and NeuroimagingAachenGermany
  5. 5.JARA-BRAIN, Jülich-Aachen Research AllianceInstitute of Brain Structure-Function RelationshipsAachenGermany
  6. 6.Department of NeurologyUniversity of UlmUlmGermany
  7. 7.Department of Psychiatry, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations